Expressed RNAi-drug developer Nucleonics has appointed Michael Young as its chief medical officer.
Young joins Nucleonics from MDY-Associates, a strategic and technical consulting group where he served as president and managing consultant. Before this, he held a number of positions in the pharmaceutical industry including corporate director of worldwide regulatory and clinical development at Procter & Gamble. He holds a PhD in chemistry from the University of Wales and an MD from the Welsh School of Medicine.